Additionally, Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction (the EMPEROR-Preserved trial), which had non-diabetic heart failure patients with preserved ejection fraction (HFpEF), and the EMPULSE trial (the SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial), which involved non-diabetic patients with acute heart failure, both showed encouraging results for symptom relief and health-related quality of life [13,14]. Here, SLC5A2 is linked to heart failure.